2 Red-Hot Drug Stocks Squeezing Shorts

The FDA approved Esperion's cholesterol drug marketing applications

Managing Editor
May 6, 2019 at 9:55 AM
facebook X logo linkedin


Near the top of the Nasdaq today sits Esperion Therapeutics Inc (NASDAQ:ESPR), after the Food and Drug Administration (FDA) accepted marketing applications for the company's cholesterol drug. At last check, ESPR is up 13% to trade at $48.86, on track for its best day since Oct. 26. The good news was met with a generous price-target hike to $90 from $79 at Credit Suisse, territory not seen since July 2015. 

Today's surge has the shares toppling their year-to-date breakeven level, and hurtling past resistance at their 200-day moving average. This trendline had kept a lid on rallies since a mid-March bear gap. 

A short squeeze could keep the wind at the equity's back. Short interest dropped by 13.6% in the two most recent reporting periods to 4.69 million shares. Yet this still accounts for a whopping 21.6% of the stock's total available float, and 8.3 days of pent-up buying power, at the average pace of trading. 

Then there's Axsome Therapeutics Inc (NASDAQ:AXSM), up 3.7% to trade at $18.61, and earlier nabbing a new record high of $19.25. The company announced it had expedited development programs for both its depression drug and migraine treatment.

It's been nothing short of a meteoric rise for AXSM. For reference, the shares closed at $2.82 on Dec. 31, and have only turned in four weekly losses in 2019. Since March, pullbacks have found support at the stock's ascending 20-day moving average.

Axsome could soon squeeze shorts, too. Despite the stock's climb, short interest increased by 37.4% in the two most recent reporting periods to 5.27 million shares, a new record high. This takes up 27.6% of AXSM's total available float, and is 5.6 times the average daily trading volume.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI